Gelatinase-mediated migration and invasion of cancer cells
Tóm tắt
Từ khóa
Tài liệu tham khảo
Egeblad, 2002, New functions for the matrix metalloproteinases in cancer progression, Nat. Rev., Cancer, 2, 161, 10.1038/nrc745
Vartio, 1981, A gelatin-binding 70,000-dalton glycoprotein synthesized distinctly from fibronectin by normal and malignant adherent cells, J. Biol. Chem., 256, 13085, 10.1016/S0021-9258(18)43010-4
Hipps, 1991, Purification and characterization of human 72-kDa gelatinase (type IV collagenase). Use of immunolocalisation to demonstrate the non-coordinate regulation of the 72-kDa and 95-kDa gelatinases by human fibroblasts, Biol. Chem. Hoppe-Seyler, 372, 287, 10.1515/bchm3.1991.372.1.287
Partridge, 1997, Localization and activation of type IV collagenase/gelatinase at endothelial focal contacts, Am. J. Physiol., 272, L813
Giannelli, 1997, Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5, Science, 277, 225, 10.1126/science.277.5323.225
Sopata, 1979, A latent gelatin specific proteinase of human leucocytes and its activation, Biochim. Biophys. Acta, 571, 305, 10.1016/0005-2744(79)90100-1
Murphy, 1980, The latent collagenase and gelatinase of human polymorphonuclear neutrophil leucocytes, Biochem. J., 192, 517, 10.1042/bj1920517
Vartio, 1982, Human macrophages synthesize and secrete a major 95,000-dalton gelatin-binding protein distinct from fibronectin, J. Biol. Chem., 257, 8862, 10.1016/S0021-9258(18)34209-1
Huhtala, 1990, Structure of the human type IV collagenase gene, J. Biol. Chem., 265, 11077, 10.1016/S0021-9258(19)38559-X
Huhtala, 1991, Complete structure of the human gene for 92-kDa type IV collagenase. Divergent regulation of expression for the 92- and 72-kilodalton enzyme genes in HT-1080 cells, J. Biol. Chem., 266, 16485, 10.1016/S0021-9258(18)55326-6
Hibbs, 1985, Biochemical and immunological characterization of the secreted forms of human neutrophil gelatinase, J. Biol. Chem., 260, 2493, 10.1016/S0021-9258(18)89580-1
Johansson, 1986, Identification of a plasma gelatinase in preparations of fibronectin, J. Biol. Chem., 261, 4363, 10.1016/S0021-9258(17)38507-1
Kotra, 2002, N-Glycosylation pattern of the zymogenic form of human matrix metalloproteinase-9, Bioorg. Chem., 30, 356, 10.1016/S0045-2068(02)00501-1
Rudd, 1999, Glycosylation of natural human neutrophil gelatinase B and neutrophil gelatinase B-associated lipocalin, Biochemistry, 38, 13937, 10.1021/bi991162e
Mattu, 2000, O-glycan analysis of natural human neutrophil gelatinase B using a combination of normal phase-HPLC and online tandem mass spectrometry: implications for the domain organization of the enzyme, Biochemistry, 39, 15695, 10.1021/bi001367j
Fernandez-Patron, 1999, Differential regulation of platelet aggregation by matrix metalloproteinases-9 and -2, Thromb. Haemost., 82, 1730, 10.1055/s-0037-1614906
Van den Steen, 2002, Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9), Crit. Rev. Biochem. Mol. Biol., 37, 375, 10.1080/10409230290771546
Behrendtsen, 1992, Metalloproteinases mediate extracellular matrix degradation by cells from mouse blastocyst outgrowths, Development, 114, 447, 10.1242/dev.114.2.447
Alexander, 1996, Expression and function of matrix metalloproteinases and their inhibitors at the maternal–embryonic boundary during mouse embryo implantation, Development, 122, 1723, 10.1242/dev.122.6.1723
Dubois, 2000, Gelatinase B deficiency impairs reproduction, J. Clin. Invest., 106, 627, 10.1172/JCI10910
Vu, 1998, MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes, Cell, 93, 411, 10.1016/S0092-8674(00)81169-1
Holmbeck, 1999, MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover, Cell, 99, 81, 10.1016/S0092-8674(00)80064-1
Dubois, 1999, Resistance of young gelatinase B-deficient mice to experimental autoimmune encephalomyelitis and necrotizing tail lesions, J. Clin. Invest., 104, 1507, 10.1172/JCI6886
Luttun, 2004, Loss of matrix metalloproteinase-9 or matrix metalloproteinase-12 protects apolipoprotein E-deficient mice against atherosclerotic media destruction but differentially affects plaque growth, Circulation, 109, 1408, 10.1161/01.CIR.0000121728.14930.DE
Itoh, 1998, Reduced angiogenesis and tumor progression in gelatinase A-deficient mice, Cancer Res., 58, 1048
Corry, 2002, Decreased allergic lung inflammatory cell egression and increased susceptibility to asphyxiation in MMP2-deficiency, Nat. Immunol., 3, 347, 10.1038/ni773
Oh, 2004, Mutations in two matrix metalloproteinase genes, MMP-2 and MT1-MMP, are synthetic lethal in mice, Oncogene, 5, 5
Baluk, 2004, Matrix metalloproteinase 2 and 9 expression increases in mycoplasma-infected airways but is not required for microvascular remodeling, Am. J. Physiol., Lung Cell. Mol. Physiol., 9, 9
Corry, 2004, Overlapping and independent contributions of MMP2 and MMP9 to lung allergic inflammatory cell egression through decreased CC chemokines, FASEB J., 18, 995, 10.1096/fj.03-1412fje
Legrand, 1999, Airway epithelial cell migration dynamics. MMP-9 role in cell-extracellular matrix remodeling, J. Cell Biol., 146, 517, 10.1083/jcb.146.2.517
Mohan, 2002, Matrix metalloproteinase gelatinase B (MMP-9) coordinates and effects epithelial regeneration, J. Biol. Chem., 277, 2065, 10.1074/jbc.M107611200
Salo, 1994, Expression of matrix metalloproteinase-2 and -9 during early human wound healing, Lab. Invest., 70, 176
Bergers, 2000, Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis, Nat. Cell Biol., 2, 737, 10.1038/35036374
Bello, 2001, Simultaneous inhibition of glioma angiogenesis, cell proliferation, and invasion by a naturally occurring fragment of human metalloproteinase-2, Cancer Res., 61, 8730
Wielockx, 2001, Inhibition of matrix metalloproteinases blocks lethal hepatitis and apoptosis induced by tumor necrosis factor and allows safe antitumor therapy, Nat. Med., 7, 1202, 10.1038/nm1101-1202
Stocker, 1995, The metzincins—Topological and sequential relations between the astacins, adamalysins, serralysins, and matrixins (collagenases) define a superfamily of zinc-peptidases, Protein Sci., 4, 823, 10.1002/pro.5560040502
Butler, 2004, The canonical methionine 392 of matrix metalloproteinase 2 (Gelatinase A) is not required for catalytic efficiency or structural integrity: probing the role of the methionine-turn in the metzincin metalloprotease superfamily, J. Biol. Chem., 279, 15615, 10.1074/jbc.M312727200
Morgunova, 1999, Structure of human pro-matrix metalloproteinase-2: activation mechanism revealed, Science, 284, 1667, 10.1126/science.284.5420.1667
Bu, 1996, Mechanism of Ca2+-dependent activity of human neutrophil gelatinase B, J. Biol. Chem., 271, 14308, 10.1074/jbc.271.24.14308
Gomis-Ruth, 2004, vol. 3, 631
Knauper, 1997, Analysis of the contribution of the hinge region of human neutrophil collagenase (HNC, MMP-8) to stability and collagenolytic activity by alanine scanning mutagenesis, FEBS Lett., 405, 60, 10.1016/S0014-5793(97)00158-0
Cha, 2002, Structural basis of the adaptive molecular recognition by MMP9, J. Mol. Biol., 320, 1065, 10.1016/S0022-2836(02)00558-2
Lehti, 2002, Oligomerization through hemopexin and cytoplasmic domains regulates the activity and turnover of membrane-type 1 matrix metalloproteinase, J. Biol. Chem., 277, 8440, 10.1074/jbc.M109128200
Goldberg, 1992, Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin, J. Biol. Chem., 267, 4583, 10.1016/S0021-9258(18)42873-6
Pei, 2000, Cysteine array matrix metalloproteinase (CA-MMP)/MMP-23 is a type II transmembrane matrix metalloproteinase regulated by a single cleavage for both secretion and activation, J. Biol. Chem., 275, 33988, 10.1074/jbc.M006493200
Steffensen, 1995, Extracellular matrix binding properties of recombinant fibronectin type II-like modules of human 72-kDa gelatinase/type IV collagenase. High affinity binding to native type I collagen but not native type IV collagen, J. Biol. Chem., 270, 11555, 10.1074/jbc.270.19.11555
Berton, 2001, Involvement of fibronectin type II repeats in the efficient inhibition of gelatinases A and B by long-chain unsaturated fatty acids, J. Biol. Chem., 276, 20458, 10.1074/jbc.M011664200
Bein, 2000, Thrombospondin type 1 repeats interact with matrix metalloproteinase 2. Regulation of metalloproteinase activity, J. Biol. Chem., 275, 32167, 10.1074/jbc.M003834200
Morgunova, 2002, Structural insight into the complex formation of latent matrix metalloproteinase 2 with tissue inhibitor of metalloproteinase 2, Proc. Natl. Acad. Sci. U. S. A., 99, 7414, 10.1073/pnas.102185399
Elkins, 2002, Structure of the C-terminally truncated human ProMMP9, a gelatin-binding matrix metalloproteinase, Acta Crystallogr., D Biol. Crystallogr., 58, 1182, 10.1107/S0907444902007849
Rowsell, 2002, Crystal structure of human MMP9 in complex with a reverse hydroxamate inhibitor, J. Mol. Biol., 319, 173, 10.1016/S0022-2836(02)00262-0
Chen, 2002, A unique substrate recognition profile for matrix metalloproteinase-2, J. Biol. Chem., 277, 4485, 10.1074/jbc.M109469200
Kridel, 2001, Substrate hydrolysis by matrix metalloproteinase-9, J. Biol. Chem., 276, 20572, 10.1074/jbc.M100900200
Chen, 2003, A residue in the S2 subsite controls substrate selectivity of matrix metalloproteinase-2 and matrix metalloproteinase-9, J. Biol. Chem., 278, 17158, 10.1074/jbc.M210324200
Allan, 1995, Binding of gelatinases A and B to type-I collagen and other matrix components, Biochem. J., 309, 299, 10.1042/bj3090299
Allan, 1991, Binding of latent and high Mr active forms of stromelysin to collagen is mediated by the C-terminal domain, J. Cell. Sci., 99, 789, 10.1242/jcs.99.4.789
Collier, 2001, Substrate recognition by gelatinase A: the C-terminal domain facilitates surface diffusion, Biophys. J., 81, 2370, 10.1016/S0006-3495(01)75883-3
Roeb, 2002, The matrix metalloproteinase 9 (mmp-9) hemopexin domain is a novel gelatin binding domain and acts as an antagonist, J. Biol. Chem., 277, 50326, 10.1074/jbc.M207446200
Patterson, 2001, Specific collagenolysis by gelatinase A, MMP-2, is determined by the hemopexin domain and not the fibronectin-like domain, FEBS Lett., 503, 158, 10.1016/S0014-5793(01)02723-5
McQuibban, 2000, Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3, Science, 289, 1202, 10.1126/science.289.5482.1202
Collier, 1992, Alanine scanning mutagenesis and functional analysis of the fibronectin-like collagen-binding domain from human 92-kDa type IV collagenase, J. Biol. Chem., 267, 6776, 10.1016/S0021-9258(19)50493-8
Tordai, 1999, The gelatin-binding site of the second type-II domain of gelatinase A/MMP-2, Eur. J. Biochem., 259, 513, 10.1046/j.1432-1327.1999.00070.x
Briknarova, 1999, The second type II module from human matrix metalloproteinase 2: structure, function and dynamics, Struct. Fold. Des., 7, 1235, 10.1016/S0969-2126(00)80057-X
Briknarova, 2001, Gelatin-binding region of human matrix metalloproteinase-2: solution structure, dynamics, and function of the COL-23 two-domain construct, J. Biol. Chem., 276, 27613, 10.1074/jbc.M101105200
Gehrmann, 2002, The col-1 module of human matrix metalloproteinase-2 (MMP-2): structural/functional relatedness between gelatin-binding fibronectin type II modules and lysine-binding kringle domains, Biol. Chem., 383, 137, 10.1515/BC.2002.014
Trexler, 2003, Peptide ligands for the fibronectin type II modules of matrix metalloproteinase 2 (MMP-2), J. Biol. Chem., 278, 12241, 10.1074/jbc.M210116200
Bjorklund, 2004, Peptide inhibition of catalytic and noncatalytic activities of matrix metalloproteinase-9 blocks tumor cell migration and invasion, J. Biol. Chem., 279, 29589, 10.1074/jbc.M401601200
Overall, 2002, Molecular determinants of metalloproteinase substrate specificity: matrix metalloproteinase substrate binding domains, modules, and exosites, Mol. Biotechnol., 22, 51, 10.1385/MB:22:1:051
Gehrmann, 2004, Modular autonomy, ligand specificity, and functional cooperativity of the three in-tandem fibronectin type II repeats from human matrix metalloproteinase 2, J. Biol. Chem., 17, 17
Birkedal-Hansen, 1993, Matrix metalloproteinases: a review, Crit. Rev. Oral Biol. Med., 4, 197, 10.1177/10454411930040020401
Sato, 1993, Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells, Oncogene, 8, 395
Westermarck, 1999, Regulation of matrix metalloproteinase expression in tumor invasion, FASEB J., 13, 781, 10.1096/fasebj.13.8.781
Kupferman, 2000, Matrix metalloproteinase 9 promoter activity is induced coincident with invasion during tumor progression, Am. J. Pathol., 157, 1777, 10.1016/S0002-9440(10)64815-8
Caudroy, 2002, EMMPRIN-mediated MMP regulation in tumor and endothelial cells, Clin. Exp. Metastasis, 19, 697, 10.1023/A:1021350718226
Guo, 2000, EMMPRIN (CD147), an inducer of matrix metalloproteinase synthesis, also binds interstitial collagenase to the tumor cell surface, Cancer Res., 60, 888
Fedarko, 2004, Three small integrin binding ligand N-linked glycoproteins (SIBLINGs) bind and activate specific matrix metalloproteinases, FASEB J., 18, 734, 10.1096/fj.03-0966fje
Werb, 1989, Signal transduction through the fibronectin receptor induces collagenase and stromelysin gene expression, J. Cell Biol., 109, 877, 10.1083/jcb.109.2.877
Riikonen, 1995, Integrin alpha 2 beta 1 is a positive regulator of collagenase (MMP-1) and collagen alpha 1(I) gene expression, J. Biol. Chem., 270, 13548, 10.1074/jbc.270.22.13548
Dumin, 2001, Pro-collagenase-1 (matrix metalloproteinase-1) binds the alpha(2)beta(1) integrin upon release from keratinocytes migrating on type I collagen, J. Biol. Chem., 276, 29368, 10.1074/jbc.M104179200
Sugiura, 1999, Function of alpha3beta1–tetraspanin protein complexes in tumor cell invasion. Evidence for the role of the complexes in production of matrix metalloproteinase 2 (MMP-2), J. Cell Biol., 146, 1375, 10.1083/jcb.146.6.1375
Wize, 1998, Ligation of selectin L and integrin CD11b/CD18 (Mac-1) induces release of gelatinase B (MMP-9) from human neutrophils, Inflamm. Res., 47, 325, 10.1007/s000110050336
Larjava, 1993, Anti-integrin antibodies induce type IV collagenase expression in keratinocytes, J. Cell. Physiol., 157, 190, 10.1002/jcp.1041570125
Yakubenko, 2000, Differential induction of gelatinase B (MMP-9) and gelatinase A (MMP-2) in T lymphocytes upon alpha(4)beta(1)-mediated adhesion to VCAM-1 and the CS-1 peptide of fibronectin, Exp. Cell Res., 260, 73, 10.1006/excr.2000.5002
Borregaard, 1997, Development of neutrophil granule diversity, Ann. N. Y. Acad. Sci., 832, 62, 10.1111/j.1749-6632.1997.tb46237.x
Cowland, 1999, The individual regulation of granule protein mRNA levels during neutrophil maturation explains the heterogeneity of neutrophil granules, J. Leukoc. Biol., 66, 989, 10.1002/jlb.66.6.989
Stefanidakis, 2004, Intracellular and cell surface localization of a complex between alphaMbeta2 integrin and promatrix metalloproteinase-9 progelatinase in neutrophils, J. Immunol., 172, 7060, 10.4049/jimmunol.172.11.7060
Dolo, 1999, Matrix-degrading proteinases are shed in membrane vesicles by ovarian cancer cells in vivo and in vitro, Clin. Exp. Metastasis, 17, 131, 10.1023/A:1006500406240
Ginestra, 1997, Urokinase plasminogen activator and gelatinases are associated with membrane vesicles shed by human HT1080 fibrosarcoma cells, J. Biol. Chem., 272, 17216, 10.1074/jbc.272.27.17216
Taraboletti, 2002, Shedding of the matrix metalloproteinases MMP-2, MMP-9, and MT1-MMP as membrane vesicle-associated components by endothelial cells, Am. J. Pathol., 160, 673, 10.1016/S0002-9440(10)64887-0
DiPersio, 2000, Mouse keratinocytes immortalized with large T antigen acquire alpha3beta1 integrin-dependent secretion of MMP-9/gelatinase B, J. Cell. Sci., 113, 2909, 10.1242/jcs.113.16.2909
Huang, 2000, Cell growth and matrix invasion of EBV-immortalized human B lymphocytes is regulated by expression of alpha(v) integrins, Oncogene, 19, 1915, 10.1038/sj.onc.1203509
Agrez, 1999, The alpha v beta 6 integrin induces gelatinase B secretion in colon cancer cells, Int. J. Cancer, 81, 90, 10.1002/(SICI)1097-0215(19990331)81:1<90::AID-IJC16>3.0.CO;2-K
Niu, 1998, Integrin-mediated signalling of gelatinase B secretion in colon cancer cells, Biochem. Biophys. Res. Commun., 249, 287, 10.1006/bbrc.1998.9128
Ahmed, 2003, Proteomic profiling of proteins associated with urokinase plasminogen activator receptor in a colon cancer cell line using an antisense approach, Proteomics, 3, 288, 10.1002/pmic.200390042
Aguirre Ghiso, 1999, Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling, J. Cell Biol., 147, 89, 10.1083/jcb.147.1.89
Monea, 2002, Plasmin activates pro-matrix metalloproteinase-2 with a membrane-type 1 matrix metalloproteinase-dependent mechanism, J. Cell. Physiol., 192, 160, 10.1002/jcp.10126
Sato, 1996, Activation of a recombinant membrane type 1-matrix metalloproteinase (MT1-MMP) by furin and its interaction with tissue inhibitor of metalloproteinases (TIMP)-2, FEBS Lett., 393, 101, 10.1016/0014-5793(96)00861-7
Yana, 2000, Regulation of membrane type-1 matrix metalloproteinase activation by proprotein convertases, Mol. Biol. Cell, 11, 2387, 10.1091/mbc.11.7.2387
Ellis, 2003, Plasminogen activation at the cell surface, vol. 54, 263
Van Wart, 1990, The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family, Proc. Natl. Acad. Sci. U. S. A., 87, 5578, 10.1073/pnas.87.14.5578
Strongin, 1995, Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease, J. Biol. Chem., 270, 5331, 10.1074/jbc.270.10.5331
Lehti, 1998, Proteolytic processing of membrane-type-1 matrix metalloproteinase is associated with gelatinase A activation at the cell surface, Biochem. J., 334, 345, 10.1042/bj3340345
Pei, 1996, Transmembrane-deletion mutants of the membrane-type matrix metalloproteinase-1 process progelatinase A and express intrinsic matrix-degrading activity, J. Biol. Chem., 271, 9135, 10.1074/jbc.271.15.9135
Yan, 2000, Adhesion-dependent control of matrix metalloproteinase-2 activation in human capillary endothelial cells, J. Cell. Sci., 113, 3979, 10.1242/jcs.113.22.3979
Brooks, 1996, Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3, Cell, 85, 683, 10.1016/S0092-8674(00)81235-0
Deryugina, 2001, MT1-MMP initiates activation of pro-MMP-2 and integrin alphavbeta3 promotes maturation of MMP-2 in breast carcinoma cells, Exp. Cell Res., 263, 209, 10.1006/excr.2000.5118
Haas, 1998, Three-dimensional type I collagen lattices induce coordinate expression of matrix metalloproteinases MT1-MMP and MMP-2 in microvascular endothelial cells, J. Biol. Chem., 273, 3604, 10.1074/jbc.273.6.3604
Stanton, 1998, The activation of ProMMP-2 (gelatinase A) by HT1080 fibrosarcoma cells is promoted by culture on a fibronectin substrate and is concomitant with an increase in processing of MT1-MMP (MMP-14) to a 45 kDa form, J. Cell. Sci., 111, 2789, 10.1242/jcs.111.18.2789
Sang, 1996, Activation of human progelatinase A by collagenase and matrilysin: activation of procollagenase by matrilysin, J. Protein Chem., 15, 243, 10.1007/BF01887112
Nguyen, 2000, Activated protein C directly activates human endothelial gelatinase A, J. Biol. Chem., 275, 9095, 10.1074/jbc.275.13.9095
Okada, 1990, Matrix metalloproteinase 2 from human rheumatoid synovial fibroblasts. Purification and activation of the precursor and enzymic properties, Eur. J. Biochem., 194, 721, 10.1111/j.1432-1033.1990.tb19462.x
Shamamian, 2000, Neutrophil-derived serine proteinases enhance membrane type-1 matrix metalloproteinase-dependent tumor cell invasion, Surgery, 127, 142, 10.1067/msy.2000.101155
Overall, 1990, Concanavalin A produces a matrix-degradative phenotype in human fibroblasts. Induction and endogenous activation of collagenase, 72-kDa gelatinase, and Pump-1 is accompanied by the suppression of the tissue inhibitor of matrix metalloproteinases, J. Biol. Chem., 265, 21141, 10.1016/S0021-9258(17)45338-5
Jiang, 2001, Regulation of membrane-type matrix metalloproteinase 1 activity by dynamin-mediated endocytosis, Proc. Natl. Acad. Sci. U. S. A., 98, 13693, 10.1073/pnas.241293698
Lee, 1997, Intracellular activation of gelatinase A (72-kDa type IV collagenase) by normal fibroblasts, Proc. Natl. Acad. Sci. U. S. A., 94, 4424, 10.1073/pnas.94.9.4424
Ramos-DeSimone, 1999, Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion, J. Biol. Chem., 274, 13066, 10.1074/jbc.274.19.13066
Lijnen, 1998, Stromelysin-1 (MMP-3)-independent gelatinase expression and activation in mice, Blood, 91, 2045, 10.1182/blood.V91.6.2045
Mazzieri, 1997, Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants, EMBO J., 16, 2319, 10.1093/emboj/16.9.2319
Toth, 2003, Pro-MMP-9 activation by the MT1-MMP/MMP-2 axis and MMP-3: role of TIMP-2 and plasma membranes, Biochem. Biophys. Res. Commun., 308, 386, 10.1016/S0006-291X(03)01405-0
Carmeliet, 1997, Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation, Nat. Genet., 17, 439, 10.1038/ng1297-439
Sorsa, 1997, Activation of type IV procollagenases by human tumor-associated trypsin-2, J. Biol. Chem., 272, 21067, 10.1074/jbc.272.34.21067
Han, 2002, Tumor necrosis factor-alpha-induced proteolytic activation of pro-matrix metalloproteinase-9 by human skin is controlled by down-regulating tissue inhibitor of metalloproteinase-1 and mediated by tissue-associated chymotrypsin-like proteinase, J. Biol. Chem., 277, 27319, 10.1074/jbc.M202842200
Fang, 1997, Dog mast cell alpha-chymase activates progelatinase B by cleaving the Phe88-Gln89 and Phe91-Glu92 bonds of the catalytic domain, J. Biol. Chem., 272, 25628, 10.1074/jbc.272.41.25628
Coussens, 1999, Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis, Genes Dev., 13, 1382, 10.1101/gad.13.11.1382
Tchougounova, 2005, A key role for mast cell chymase in the activation of pro-matrix metalloprotease-9 and pro-matrix Metalloprotease-2, J. Biol. Chem., 280, 9291, 10.1074/jbc.M410396200
Fridman, 1995, Activation of progelatinase B (MMP-9) by gelatinase A (MMP-2), Cancer Res., 55, 2548
Ogata, 1992, Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9, J. Biol. Chem., 267, 3581, 10.1016/S0021-9258(19)50563-4
von Bredow, 1998, Activation of gelatinase-tissue-inhibitors-of-metalloproteinase complexes by matrilysin, Biochem. J., 331, 965, 10.1042/bj3310965
Nakamura, 1998, Activation of the precursor of human stromelysin 2 and its interactions with other matrix metalloproteinases, Eur. J. Biochem., 253, 67, 10.1046/j.1432-1327.1998.2530067.x
Knauper, 1997, Activation of progelatinase B (proMMP-9) by active collagenase-3 (MMP-13), Eur. J. Biochem., 248, 369, 10.1111/j.1432-1033.1997.00369.x
Zhao, 2003, Activation of pro-gelatinase B by endometase/matrilysin-2 promotes invasion of human prostate cancer cells, J. Biol. Chem., 278, 15056, 10.1074/jbc.M210975200
Bannikov, 2002, Substrate binding of gelatinase B induces its enzymatic activity in the presence of intact propeptide, J. Biol. Chem., 277, 16022, 10.1074/jbc.M110931200
Peppin, 1986, Activation of the endogenous metalloproteinase, gelatinase, by triggered human neutrophils, Proc. Natl. Acad. Sci. U. S. A., 83, 4322, 10.1073/pnas.83.12.4322
Gu, 2002, S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death, Science, 297, 1186, 10.1126/science.1073634
Paquette, 2003, Activation of matrix metalloproteinase-2 and -9 by 2- and 4-hydroxyestradiol, J. Steroid Biochem. Mol. Biol., 87, 65, 10.1016/S0960-0760(03)00386-8
Triebel, 1992, Mercurial activation of human PMN leucocyte type IV procollagenase (gelatinase), FEBS Lett., 298, 280, 10.1016/0014-5793(92)80077-T
Sottrup-Jensen, 1989, Human fibroblast collagenase-alpha-macroglobulin interactions. Localization of cleavage sites in the bait regions of five mammalian alpha-macroglobulins, J. Biol. Chem., 264, 393, 10.1016/S0021-9258(17)31271-1
Morodomi, 1992, Purification and characterization of matrix metalloproteinase 9 from U937 monocytic leukaemia and HT1080 fibrosarcoma cells, Biochem. J., 285, 603, 10.1042/bj2850603
Moestrup, 1993, Alpha 2-macroglobulin–proteinase complexes, plasminogen activator inhibitor type-1-plasminogen activator complexes, and receptor-associated protein bind to a region of the alpha 2-macroglobulin receptor containing a cluster of eight complement-type repeats, J. Biol. Chem., 268, 13691, 10.1016/S0021-9258(19)38702-2
Yang, 2001, Extracellular matrix metalloproteinase 2 levels are regulated by the low density lipoprotein-related scavenger receptor and thrombospondin 2, J. Biol. Chem., 276, 8403, 10.1074/jbc.M008925200
Hahn-Dantona, 2001, The low density lipoprotein receptor-related protein modulates levels of matrix metalloproteinase 9 (MMP-9) by mediating its cellular catabolism, J. Biol. Chem., 276, 15498, 10.1074/jbc.M100121200
O'Connell, 1994, Analysis of the role of the COOH-terminal domain in the activation, proteolytic activity, and tissue inhibitor of metalloproteinase interactions of gelatinase B, J. Biol. Chem., 269, 14967, 10.1016/S0021-9258(17)36561-4
Olson, 1997, Kinetic analysis of the binding of human matrix metalloproteinase-2 and -9 to tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2, J. Biol. Chem., 272, 29975, 10.1074/jbc.272.47.29975
Amour, 2000, The in vitro activity of ADAM-10 is inhibited by TIMP-1 and TIMP-3, FEBS Lett., 473, 275, 10.1016/S0014-5793(00)01528-3
Amour, 1998, TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3, FEBS Lett., 435, 39, 10.1016/S0014-5793(98)01031-X
Wang, 2000, TIMP-2 is required for efficient activation of proMMP-2 in vivo, J. Biol. Chem., 275, 26411, 10.1074/jbc.M001270200
Ree, 1997, High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases, Clin. Cancer Res., 3, 1623
Murashige, 1996, Enhanced expression of tissue inhibitors of metalloproteinases in human colorectal tumors, Jpn. J. Clin. Oncol., 26, 303, 10.1093/oxfordjournals.jjco.a023237
Fong, 1996, TIMP1 and adverse prognosis in non-small cell lung cancer, Clin. Cancer Res., 2, 1369
Yoshizaki, 2001, Expression of tissue inhibitor of matrix metalloproteinase-2 correlates with activation of matrix metalloproteinase-2 and predicts poor prognosis in tongue squamous cell carcinoma, Int. J. Cancer, 95, 44, 10.1002/1097-0215(20010120)95:1<44::AID-IJC1008>3.0.CO;2-M
Jiang, 2001, Stimulation of mammary tumorigenesis by systemic tissue inhibitor of matrix metalloproteinase 4 gene delivery, Cancer Res., 61, 2365
Nemeth, 1996, TIMP-2 growth-stimulatory activity: a concentration- and cell type-specific response in the presence of insulin, Exp. Cell Res., 224, 110, 10.1006/excr.1996.0117
Seo, 2003, TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism, Cell, 114, 171, 10.1016/S0092-8674(03)00551-8
Qi, 2003, A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2, Nat. Med., 9, 407, 10.1038/nm846
Zhao, 1998, Cell cycle-associated accumulation of tissue inhibitor of metalloproteinases-1 (TIMP-1) in the nuclei of human gingival fibroblasts, J. Cell. Sci., 111, 1147, 10.1242/jcs.111.9.1147
Ritter, 1999, Tissue inhibitor of metalloproteinases-1 (TIMP-1) binds to the cell surface and translocates to the nucleus of human MCF-7 breast carcinoma cells, Biochem. Biophys. Res. Commun., 257, 494, 10.1006/bbrc.1999.0408
Kwan, 2004, Matrix metalloproteinase-2 (MMP-2) is present in the nucleus of cardiac myocytes and is capable of cleaving poly (ADP-ribose) polymerase (PARP) in vitro, FASEB J., 18, 690, 10.1096/fj.02-1202fje
Mott, 2000, Post-translational proteolytic processing of procollagen C-terminal proteinase enhancer releases a metalloproteinase inhibitor, J. Biol. Chem., 275, 1384, 10.1074/jbc.275.2.1384
Netzer, 1998, Comparative analysis of the noncollagenous NC1 domain of type IV collagen: identification of structural features important for assembly, function, and pathogenesis, Protein Sci., 7, 1340, 10.1002/pro.5560070610
Petitclerc, 2000, New functions for non-collagenous domains of human collagen type IV. Novel integrin ligands inhibiting angiogenesis and tumor growth in vivo, J. Biol. Chem., 275, 8051, 10.1074/jbc.275.11.8051
Pedchenko, 2003, av{beta}3 and av{beta}5 integrins bind both the proximal RGD site and non-RGD motifs within noncollagenous (NC1) domain of the a3 chain of type IV collagen: implication for the mechanism of endothelial cell adhesion, J. Biol. Chem., 10, 10
Herman, 2001, Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis, J. Clin. Invest., 107, 1117, 10.1172/JCI10403
O'Reilly, 1997, Endostatin: an endogenous inhibitor of angiogenesis and tumor growth, Cell, 88, 277, 10.1016/S0092-8674(00)81848-6
Felbor, 2000, Secreted cathepsin L generates endostatin from collagen XVIII, EMBO J., 19, 1187, 10.1093/emboj/19.6.1187
Ferreras, 2000, Generation and degradation of human endostatin proteins by various proteinases, FEBS Lett., 486, 247, 10.1016/S0014-5793(00)02249-3
Kim, 2000, Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase, Cancer Res., 60, 5410
Nyberg, 2003, Endostatin inhibits human tongue carcinoma cell invasion and intravasation and blocks the activation of matrix metalloprotease-2, -9, and -13, J. Biol. Chem., 278, 22404, 10.1074/jbc.M210325200
Takahashi, 1998, Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK, Proc. Natl. Acad. Sci. U. S. A., 95, 13221, 10.1073/pnas.95.22.13221
Oh, 2001, The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis, Cell, 107, 789, 10.1016/S0092-8674(01)00597-9
Qian, 1997, Thrombospondin-1 modulates angiogenesis in vitro by up-regulation of matrix metalloproteinase-9 in endothelial cells, Exp. Cell Res., 235, 403, 10.1006/excr.1997.3681
Rodriguez-Manzaneque, 2001, Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor, Proc. Natl. Acad. Sci. U. S. A., 98, 12485, 10.1073/pnas.171460498
Dupont, 1998, Antiangiogenic properties of a novel shark cartilage extract: potential role in the treatment of psoriasis, J. Cutan. Med. Surg., 2, 146, 10.1177/120347549800200307
Falardeau, 2001, Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials, Semin. Oncol., 28, 620, 10.1016/S0093-7754(01)90035-1
Tanzawa, 1992, Matlystatins, new inhibitors of typeIV collagenases from Actinomadura atramentaria: II. Biological activities, J. Antibiot. (Tokyo), 45, 1733, 10.7164/antibiotics.45.1733
Murono, 2000, Aspirin inhibits tumor cell invasiveness induced by Epstein–Barr virus latent membrane protein 1 through suppression of matrix metalloproteinase-9 expression, Cancer Res., 60, 2555
Jiang, 2001, Aspirin inhibits matrix metalloproteinase-2 activity, increases E-cadherin production, and inhibits in vitro invasion of tumor cells, Biochem. Biophys. Res. Commun., 282, 671, 10.1006/bbrc.2001.4637
Liu, 2002, Induction of RECK by nonsteroidal anti-inflammatory drugs in lung cancer cells, Oncogene, 21, 8347, 10.1038/sj.onc.1206017
Demeule, 2000, Matrix metalloproteinase inhibition by green tea catechins, Biochim. Biophys. Acta, 1478, 51, 10.1016/S0167-4838(00)00009-1
Ashe, 1977, Specific inhibition of human granulocyte elastase by cis-unsaturated fatty acids and activation by the corresponding alcohols, Biochem. Biophys. Res. Commun., 75, 194, 10.1016/0006-291X(77)91308-0
Higazi, 1994, Regulation of fibrinolysis by non-esterified fatty acids, Biochem. J., 300, 251, 10.1042/bj3000251
Whittaker, 1999, Design and therapeutic application of matrix metalloproteinase inhibitors, Chem. Rev., 99, 2735, 10.1021/cr9804543
Davies, 1993, A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts, Cancer Res., 53, 2087
Shalinsky, 1999, Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials, Ann. N. Y. Acad. Sci., 878, 236, 10.1111/j.1749-6632.1999.tb07689.x
Tamura, 1998, Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives, J. Med. Chem., 41, 640, 10.1021/jm9707582
Bernardo, 2002, Design, synthesis, and characterization of potent, slow-binding inhibitors that are selective for gelatinases, J. Biol. Chem., 277, 11201, 10.1074/jbc.M111021200
Rosenblum, 2003, Structural basis for potent slow binding inhibition of human matrix metalloproteinase-2 (MMP-2), J. Biol. Chem., 278, 27009, 10.1074/jbc.M301139200
Zucker, 2000, Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment, Oncogene, 19, 6642, 10.1038/sj.onc.1204097
Park, 2003, The intermediate S1′ pocket of the endometase/matrilysin-2 active site revealed by enzyme inhibition kinetic studies, protein sequence analyses, and homology modeling, J. Biol. Chem., 278, 51646, 10.1074/jbc.M310109200
Sorsa, 1998, Functional sites of chemically modified tetracyclines: inhibition of the oxidative activation of human neutrophil and chicken osteoclast pro-matrix metalloproteinases, J. Rheumatol., 25, 975
Seftor, 1998, Chemically modified tetracyclines inhibit human melanoma cell invasion and metastasis, Clin. Exp. Metastasis, 16, 217, 10.1023/A:1006588708131
Cianfrocca, 2002, Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study, J. Clin. Oncol., 20, 153, 10.1200/JCO.20.1.153
Teronen, 1999, MMP inhibition and downregulation by bisphosphonates, Ann. N. Y. Acad. Sci., 878, 453, 10.1111/j.1749-6632.1999.tb07702.x
Giraudo, 2004, An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis, J. Clin. Invest., 114, 623, 10.1172/JCI200422087
Hidalgo, 2001, Development of matrix metalloproteinase inhibitors in cancer therapy, J. Natl. Cancer Inst., 93, 178, 10.1093/jnci/93.3.178
Fotouhi, 1994, Potent peptide inhibitors of stromelysin based on the prodomain region of matrix metalloproteinases, J. Biol. Chem., 269, 30227, 10.1016/S0021-9258(18)43801-X
Koivunen, 1999, Tumor targeting with a selective gelatinase inhibitor, Nat. Biotechnol., 17, 768, 10.1038/11703
Medina, 2001, Binding of novel peptide inhibitors of type IV collagenases to phospholipid membranes and use in liposome targeting to tumor cells in vitro, Cancer Res., 61, 3978
Turunen, 2002, Peptide-retargeted adenovirus encoding a tissue inhibitor of metalloproteinase-1 decreases restenosis after intravascular gene transfer, Mol. Ther., 6, 306, 10.1006/mthe.2002.0668
Pirila, 2001, In vivo localization of gelatinases (MMP-2 and -9) by in situ zymography with a selective gelatinase inhibitor, Biochem. Biophys. Res. Commun., 287, 766, 10.1006/bbrc.2001.5653
Fernandez-Patron, 2000, Vascular matrix metalloproteinase-2-dependent cleavage of calcitonin gene-related peptide promotes vasoconstriction, Circ. Res., 87, 670, 10.1161/01.RES.87.8.670
Franzke, 2002, Transmembrane collagen XVII, an epithelial adhesion protein, is shed from the cell surface by ADAMs, EMBO J., 21, 5026, 10.1093/emboj/cdf532
Cheng, 2003, Gelatinase A (MMP-2) is necessary and sufficient for renal tubular cell epithelial–mesenchymal transformation, Am. J. Pathol., 162, 1937, 10.1016/S0002-9440(10)64327-1
Hua, 1996, Inhibition of matrix metalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma model system, Cancer Res., 56, 5279
Sehgal, 1998, Requirement for matrix metalloproteinase-9 (gelatinase B) expression in metastasis by murine prostate carcinoma, Am. J. Pathol., 152, 591
Turck, 1996, Matrix metalloproteinase 2 (gelatinase A) regulates glomerular mesangial cell proliferation and differentiation, J. Biol. Chem., 271, 15074, 10.1074/jbc.271.25.15074
Lakka, 2002, Adenovirus-mediated expression of antisense MMP-9 in glioma cells inhibits tumor growth and invasion, Oncogene, 21, 8011, 10.1038/sj.onc.1205894
Sanceau, 2003, Matrix metalloproteinase-9 silencing by RNA interference triggers the migratory-adhesive switch in Ewing's sarcoma cells, J. Biol. Chem., 278, 36537, 10.1074/jbc.M304300200
Overall, 2002, Strategies for MMP inhibition in cancer: innovations for the post-trial era, Nat. Rev., Cancer, 2, 657, 10.1038/nrc884
Chapman, 1997, Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration, Curr. Opin. Cell Biol., 9, 714, 10.1016/S0955-0674(97)80126-3
Lauffenburger, 1996, Cell migration: a physically integrated molecular process, Cell, 84, 359, 10.1016/S0092-8674(00)81280-5
Chen, 1999, Specialized surface protrusions of invasive cells, invadopodia and lamellipodia, have differential MT1-MMP, MMP-2, and TIMP-2 localization, Ann. N. Y. Acad. Sci., 878, 361, 10.1111/j.1749-6632.1999.tb07695.x
Chen, 1996, Proteases associated with invadopodia, and their role in degradation of extracellular matrix, Enzyme Protein, 49, 59, 10.1159/000468616
Mueller, 1999, A novel protease-docking function of integrin at invadopodia, J. Biol. Chem., 274, 24947, 10.1074/jbc.274.35.24947
Regen, 1992, Dynamics of beta 1 integrin-mediated adhesive contacts in motile fibroblasts, J. Cell Biol., 119, 1347, 10.1083/jcb.119.5.1347
Zamir, 2001, Molecular complexity and dynamics of cell-matrix adhesions, J. Cell. Sci., 114, 3583, 10.1242/jcs.114.20.3583
Hynes, 2002, Integrins: bidirectional, allosteric signaling machines, Cell, 110, 673, 10.1016/S0092-8674(02)00971-6
Arnaout, 2002, Coming to grips with integrin binding to ligands, Curr. Opin. Cell Biol., 14, 641, 10.1016/S0955-0674(02)00371-X
Xiong, 2002, Crystal structure of the extracellular segment of integrin alpha Vbeta3 in complex with an Arg-Gly-Asp ligand, Science, 296, 151, 10.1126/science.1069040
Ruoslahti, 1996, RGD and other recognition sequences for integrins, Annu. Rev. Cell Dev. Biol., 12, 697, 10.1146/annurev.cellbio.12.1.697
Koivunen, 1993, Selection of peptides binding to the alpha 5 beta 1 integrin from phage display library, J. Biol. Chem., 268, 20205, 10.1016/S0021-9258(20)80715-7
Koivunen, 1995, Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins, Biotechnology (New York), 13, 265, 10.1038/nbt0395-265
Healy, 1995, Peptide ligands for integrin alpha v beta 3 selected from random phage display libraries, Biochemistry, 34, 3948, 10.1021/bi00012a012
Koivunen, 2001, Inhibition of beta(2) integrin-mediated leukocyte cell adhesion by leucine-leucine-glycine motif-containing peptides, J. Cell Biol., 153, 905, 10.1083/jcb.153.5.905
Gahmberg, 1997, Leukocyte adhesion: CD11/CD18 integrins and intercellular adhesion molecules, Curr. Opin. Cell Biol., 9, 643, 10.1016/S0955-0674(97)80117-2
Bansal, 2003, Small molecule antagonists of complement receptor type 3 block adhesion and adhesion-dependent oxidative burst in human polymorphonuclear leukocytes, J. Pharmacol. Exp. Ther., 304, 1016, 10.1124/jpet.102.045286
Shimaoka, 2003, Therapeutic antagonists and conformational regulation of integrin function, Nat. Rev., Drug Discov., 2, 703, 10.1038/nrd1174
Hall, 1994, Small GTP-binding proteins and the regulation of the actin cytoskeleton, Annu. Rev. Cell Biol., 10, 31, 10.1146/annurev.cb.10.110194.000335
Ridley, 1992, The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors, Cell, 70, 389, 10.1016/0092-8674(92)90163-7
Clark, 2000, Genomic analysis of metastasis reveals an essential role for RhoC, Nature, 406, 532, 10.1038/35020106
Jaffe, 2002, Rho GTPases in transformation and metastasis, Adv. Cancer Res., 84, 57, 10.1016/S0065-230X(02)84003-9
Suyama, 2003, Identification of genes responsible for cell migration by a library of randomized ribozymes, Cancer Res., 63, 119
Weisberg, 1997, Role of focal adhesion proteins in signal transduction and oncogenesis, Crit. Rev. Oncog., 8, 343, 10.1615/CritRevOncog.v8.i4.40
Parsons, 2000, Focal adhesion kinase: a regulator of focal adhesion dynamics and cell movement, Oncogene, 19, 5606, 10.1038/sj.onc.1203877
Owens, 1995, Overexpression of the focal adhesion kinase (p125FAK) in invasive human tumors, Cancer Res., 55, 2752
Wei, 1999, A role for caveolin and the urokinase receptor in integrin-mediated adhesion and signaling, J. Cell Biol., 144, 1285, 10.1083/jcb.144.6.1285
Eliceiri, 2002, Src-mediated coupling of focal adhesion kinase to integrin alpha(v)beta5 in vascular endothelial growth factor signaling, J. Cell Biol., 157, 149, 10.1083/jcb.200109079
Hsia, 2003, Differential regulation of cell motility and invasion by FAK, J. Cell Biol., 160, 753, 10.1083/jcb.200212114
Shofuda, 2004, Cleavage of focal adhesion kinase in vascular smooth muscle cells overexpressing membrane-type matrix metalloproteinases, Arterioscler. Thromb. Vasc. Biol., 24, 839, 10.1161/01.ATV.0000126680.78500.4c
Chen, 1981, Mechanism of retraction of the trailing edge during fibroblast movement, J. Cell Biol., 90, 187, 10.1083/jcb.90.1.187
Palecek, 1996, Integrin dynamics on the tail region of migrating fibroblasts, J. Cell. Sci., 109, 941, 10.1242/jcs.109.5.941
Czekay, 2003, Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins, J. Cell Biol., 160, 781, 10.1083/jcb.200208117
Murphy-Ullrich, 2001, The de-adhesive activity of matricellular proteins: is intermediate cell adhesion an adaptive state?, J. Clin. Invest., 107, 785, 10.1172/JCI12609
Montuori, 2002, The cleavage of the urokinase receptor regulates its multiple functions, J. Biol. Chem., 277, 46932, 10.1074/jbc.M207494200
Andolfo, 2002, Metalloproteases cleave the urokinase-type plasminogen activator receptor in the D1–D2 linker region and expose epitopes not present in the intact soluble receptor, Thromb. Haemost., 88, 298, 10.1055/s-0037-1613202
Palecek, 1997, Integrin–ligand binding properties govern cell migration speed through cell-substratum adhesiveness, Nature, 385, 537, 10.1038/385537a0
Schenk, 2003, Tales from the crypt[ic] sites of the extracellular matrix, Trends Cell Biol., 13, 366, 10.1016/S0962-8924(03)00129-6
Friedl, 2000, The biology of cell locomotion within three-dimensional extracellular matrix, Cell. Mol. Life Sci., 57, 41, 10.1007/s000180050498
Mignatti, 1993, Biology and biochemistry of proteinases in tumor invasion, Physiol. Rev., 73, 161, 10.1152/physrev.1993.73.1.161
Wolf, 2003, Compensation mechanism in tumor cell migration: mesenchymal–amoeboid transition after blocking of pericellular proteolysis, J. Cell Biol., 160, 267, 10.1083/jcb.200209006
Yu, 2000, Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis, Genes Dev., 14, 163, 10.1101/gad.14.2.163
Stetler-Stevenson, 2001, Proteases in invasion: matrix metalloproteinases, Semin. Cancer Biol., 11, 143, 10.1006/scbi.2000.0365
Cao, 2004, Distinct roles for the catalytic and hemopexin domains of membrane type 1-matrix metalloproteinase in substrate degradation and cell migration, J. Biol. Chem., 279, 14129, 10.1074/jbc.M312120200
Betsuyaku, 1999, Neutrophil emigration in the lungs, peritoneum, and skin does not require gelatinase B, Am. J. Respir. Cell Mol. Biol., 20, 1303, 10.1165/ajrcmb.20.6.3558
D'Haese, 2000, In vivo neutrophil recruitment by granulocyte chemotactic protein-2 is assisted by gelatinase B/MMP-9 in the mouse, J. Interferon Cytokine Res., 20, 667, 10.1089/107999000414853
Stam, 1998, Invasion of T-lymphoma cells: cooperation between Rho family GTPases and lysophospholipid receptor signaling, EMBO J., 17, 4066, 10.1093/emboj/17.14.4066
Abecassis, 2003, RhoA induces MMP-9 expression at CD44 lamellipodial focal complexes and promotes HMEC-1 cell invasion, Exp. Cell Res., 291, 363, 10.1016/j.yexcr.2003.08.006
Banyard, 2000, Motility and invasion are differentially modulated by Rho family GTPases, Oncogene, 19, 580, 10.1038/sj.onc.1203338
Lin, 1999, Specific contributions of the small GTPases Rho, Rac, and Cdc42 to Dbl transformation, J. Biol. Chem., 274, 23633, 10.1074/jbc.274.33.23633
Ray, 1995, Gelatinase A activity directly modulates melanoma cell adhesion and spreading, EMBO J., 14, 908, 10.1002/j.1460-2075.1995.tb07072.x
Ho, 2001, MMP inhibitors augment fibroblast adhesion through stabilization of focal adhesion contacts and up-regulation of cadherin function, J. Biol. Chem., 276, 40215, 10.1074/jbc.M101647200
Werb, 1997, ECM and cell surface proteolysis: regulating cellular ecology, Cell, 91, 439, 10.1016/S0092-8674(00)80429-8
Liou, 1996, Quantum proteolysis resulting from release of single granules by human neutrophils: a novel, nonoxidative mechanism of extracellular proteolytic activity, J. Immunol., 157, 2624, 10.4049/jimmunol.157.6.2624
Olson, 1998, High affinity binding of latent matrix metalloproteinase-9 to the alpha2(IV) chain of collagen IV, J. Biol. Chem., 273, 10672, 10.1074/jbc.273.17.10672
Makela, 1998, MMP-9 from TNF alpha-stimulated keratinocytes binds to cell membranes and type I collagen: a cause for extended matrix degradation in inflammation?, Biochem. Biophys. Res. Commun., 253, 325, 10.1006/bbrc.1998.9641
Toth, 1997, Phorbol ester-induced cell surface association of matrix metalloproteinase-9 in human MCF10A breast epithelial cells, Cancer Res., 57, 3159
Mira, 1999, Insulin-like growth factor I-triggered cell migration and invasion are mediated by matrix metalloproteinase-9, Endocrinology, 140, 1657, 10.1210/en.140.4.1657
Gaudin, 1997, Proteolytic potential of human neutrophil membranes, Eur. J. Cell Biol., 72, 345
Owen, 2003, Inducible expression of tissue inhibitor of metalloproteinases-resistant matrix metalloproteinase-9 on the cell surface of neutrophils, Am. J. Respir. Cell Mol. Biol., 29, 283, 10.1165/rcmb.2003-0034OC
Zucker, 1990, Extraction of type-IV collagenase/gelatinase from plasma membranes of human cancer cells, Int. J. Cancer, 45, 1137, 10.1002/ijc.2910450625
Ellerbroek, 2001, Phosphatidylinositol 3-kinase activity in epidermal growth factor-stimulated matrix metalloproteinase-9 production and cell surface association, Cancer Res., 61, 1855
Festuccia, 2000, Osteoblast-derived TGF-beta1 modulates matrix degrading protease expression and activity in prostate cancer cells, Int. J. Cancer, 85, 407, 10.1002/(SICI)1097-0215(20000201)85:3<407::AID-IJC18>3.0.CO;2-8
Yu, 1999, Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion, Genes Dev., 13, 35, 10.1101/gad.13.1.35
Fiore, 2002, Matrix metalloproteinase 9 (MMP-9/gelatinase B) proteolytically cleaves ICAM-1 and participates in tumor cell resistance to natural killer cell-mediated cytotoxicity, Oncogene, 21, 5213, 10.1038/sj.onc.1205684
Toth, 1999, Biosynthesis of alpha2(IV) and alpha1(IV) chains of collagen IV and interactions with matrix metalloproteinase-9, J. Cell. Physiol., 180, 131, 10.1002/(SICI)1097-4652(199907)180:1<131::AID-JCP15>3.0.CO;2-S
Saad, 2002, Cancer cell-associated fibronectin induces release of matrix metalloproteinase-2 from normal fibroblasts, Cancer Res., 62, 283
Steffensen, 1998, The involvement of the fibronectin type II-like modules of human gelatinase A in cell surface localization and activation, J. Biol. Chem., 273, 20622, 10.1074/jbc.273.32.20622
Kajita, 2001, Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration, J. Cell Biol., 153, 893, 10.1083/jcb.153.5.893
Spessotto, 2002, Hyaluronan-CD44 interaction hampers migration of osteoclast-like cells by down-regulating MMP-9, J. Cell Biol., 158, 1133, 10.1083/jcb.200202120
Mori, 2002, CD44 directs membrane-type 1 matrix metalloproteinase to lamellipodia by associating with its hemopexin-like domain, EMBO J., 21, 3949, 10.1093/emboj/cdf411
Bourguignon, 1998, CD44v(3,8–10) is involved in cytoskeleton-mediated tumor cell migration and matrix metalloproteinase (MMP-9) association in metastatic breast cancer cells, J. Cell. Physiol., 176, 206, 10.1002/(SICI)1097-4652(199807)176:1<206::AID-JCP22>3.0.CO;2-3
Nakahara, 1997, Transmembrane/cytoplasmic domain-mediated membrane type 1-matrix metalloprotease docking to invadopodia is required for cell invasion, Proc. Natl. Acad. Sci. U. S. A., 94, 7959, 10.1073/pnas.94.15.7959
Morrison, 2001, Cellular activation of MMP-2 (gelatinase A) by MT2-MMP occurs via a TIMP-2-independent pathway, J. Biol. Chem., 276, 47402, 10.1074/jbc.M108643200
Eustace, 2004, Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness, Nat. Cell Biol., 6, 507, 10.1038/ncb1131
Monferran, 2004, The membrane form of the DNA repair protein Ku interacts at the cell surface with metalloproteinase 9, EMBO J., 23, 3758, 10.1038/sj.emboj.7600403
Puyraimond, 2001, MMP-2 colocalizes with caveolae on the surface of endothelial cells, Exp. Cell Res., 262, 28, 10.1006/excr.2000.5069
Nabeshima, 2000, Front-cell-specific expression of membrane-type 1 matrix metalloproteinase and gelatinase A during cohort migration of colon carcinoma cells induced by hepatocyte growth factor/scatter factor, Cancer Res., 60, 3364
Brooks, 1998, Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity, Cell, 92, 391, 10.1016/S0092-8674(00)80931-9
Pfeifer, 2000, Suppression of angiogenesis by lentiviral delivery of PEX, a noncatalytic fragment of matrix metalloproteinase 2, Proc. Natl. Acad. Sci. U. S. A., 97, 12227, 10.1073/pnas.220399597
Silletti, 2001, Disruption of matrix metalloproteinase 2 binding to integrin alpha vbeta 3 by an organic molecule inhibits angiogenesis and tumor growth in vivo, Proc. Natl. Acad. Sci. U. S. A., 98, 119, 10.1073/pnas.011343298
Boger, 2001, Identification of a novel class of small-molecule antiangiogenic agents through the screening of combinatorial libraries which function by inhibiting the binding and localization of proteinase MMP2 to integrin alpha(V)beta(3), J. Am. Chem. Soc., 123, 1280, 10.1021/ja003579+
Maeshima, 2001, Extracellular matrix-derived peptide binds to alpha(v)beta(3) integrin and inhibits angiogenesis, J. Biol. Chem., 276, 31959, 10.1074/jbc.M103024200
Wang, 2003, Ganglioside GM3 inhibits matrix metalloproteinase-9 activation and disrupts its association with integrin, J. Biol. Chem., 30, 30
Dolo, 2000, Enrichment and localization of ganglioside G(D3) and caveolin-1 in shed tumor cell membrane vesicles, Biochim. Biophys. Acta, 1486, 265, 10.1016/S1388-1981(00)00063-9
Rolli, 2003, Activated integrin {alpha}v{beta}3 cooperates with metalloproteinase MMP-9 in regulating migration of metastatic breast cancer cells, Proc. Natl. Acad. Sci. U. S. A., 21, 21
Morini, 2000, The alpha 3 beta 1 integrin is associated with mammary carcinoma cell metastasis, invasion, and gelatinase B (MMP-9) activity, Int. J. Cancer, 87, 336, 10.1002/1097-0215(20000801)87:3<336::AID-IJC5>3.0.CO;2-3
Brooks, 1997, Insulin-like growth factor receptor cooperates with integrin alpha v beta 5 to promote tumor cell dissemination in vivo, J. Clin. Invest., 99, 1390, 10.1172/JCI119298
Friedlander, 1995, Definition of two angiogenic pathways by distinct alpha v integrins, Science, 270, 1500, 10.1126/science.270.5241.1500
Stefanidakis, 2003, Identification of a negatively charged peptide motif within the catalytic domain of progelatinases that mediates binding to leukocyte beta 2 integrins, J. Biol. Chem., 278, 34674, 10.1074/jbc.M302288200
Morgan, 2004, The integrin cytoplasmic-tail motif EKQKVDLSTDC is sufficient to promote tumor cell invasion mediated by matrix metalloproteinase (MMP)-2 or MMP-9, J. Biol. Chem., 279, 26533, 10.1074/jbc.M401736200
Takagi, 2001, Definition of EGF-like, closely interacting modules that bear activation epitopes in integrin beta subunits, Proc. Natl. Acad. Sci. U. S. A., 98, 11175, 10.1073/pnas.201420198
Beglova, 2002, Cysteine-rich module structure reveals a fulcrum for integrin rearrangement upon activation, Nat. Struct. Biol., 9, 282, 10.1038/nsb779
Stricker, 2001, Structural analysis of the alpha(2) integrin I domain/procollagenase-1 (matrix metalloproteinase-1) interaction, J. Biol. Chem., 276, 29375, 10.1074/jbc.M102217200
Wei, 1996, Regulation of integrin function by the urokinase receptor, Science, 273, 1551, 10.1126/science.273.5281.1551
Xue, 1997, Urokinase-type plasminogen activator receptors associate with beta1 and beta3 integrins of fibrosarcoma cells: dependence on extracellular matrix components, Cancer Res., 57, 1682
Carriero, 1999, Urokinase receptor interacts with alpha(v)beta5 vitronectin receptor, promoting urokinase-dependent cell migration in breast cancer, Cancer Res., 59, 5307
Wei, 2001, Urokinase receptors promote beta1 integrin function through interactions with integrin alpha3beta1, Mol. Biol. Cell, 12, 2975, 10.1091/mbc.12.10.2975
Yu, 1997, Reduction in surface urokinase receptor forces malignant cells into a protracted state of dormancy, J. Cell Biol., 137, 767, 10.1083/jcb.137.3.767
Prager, 2003, Vascular endothelial growth factor (VEGF) induces rapid pro-urokinase (pro-uPA) activation on the surface of endothelial cells, Blood, 2, 2
Solberg, 1994, A cleaved form of the receptor for urokinase-type plasminogen activator in invasive transplanted human and murine tumors, Int. J. Cancer, 58, 877, 10.1002/ijc.2910580622
Mustjoki, 2000, Soluble urokinase receptor levels correlate with number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy, Cancer Res., 60, 7126
Fazioli, 1997, A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity, EMBO J., 16, 7279, 10.1093/emboj/16.24.7279
Hoyer-Hansen, 1992, Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain, J. Biol. Chem., 267, 18224, 10.1016/S0021-9258(19)37176-5
Koolwijk, 2001, Proteolysis of the urokinase-type plasminogen activator receptor by metalloproteinase-12: implication for angiogenesis in fibrin matrices, Blood, 97, 3123, 10.1182/blood.V97.10.3123
Kim, 1998, Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay, Cell, 94, 353, 10.1016/S0092-8674(00)81478-6
van den Oord, 1997, Expression of gelatinase B and the extracellular matrix metalloproteinase inducer EMMPRIN in benign and malignant pigment cell lesions of the skin, Am. J. Pathol., 151, 665
Pacheco, 1998, Expression of gelatinases A and B, stromelysin-3 and matrilysin genes in breast carcinomas: clinico-pathological correlations, Clin. Exp. Metastasis, 16, 577, 10.1023/A:1006580415796
Scorilas, 2001, Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients, Br. J. Cancer, 84, 1488, 10.1054/bjoc.2001.1810
Zeng, 1996, Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9, J. Clin. Oncol., 14, 3133, 10.1200/JCO.1996.14.12.3133
Takeha, 1997, Stromal expression of MMP-9 and urokinase receptor is inversely associated with liver metastasis and with infiltrating growth in human colorectal cancer: a novel approach from immune/inflammatory aspect, Jpn. J. Cancer Res., 88, 72, 10.1111/j.1349-7006.1997.tb00304.x
Folkman, 1992, The role of angiogenesis in tumor growth, Semin. Cancer Biol., 3, 65
Veikkola, 1999, VEGFs, receptors and angiogenesis, Semin. Cancer Biol., 9, 211, 10.1006/scbi.1998.0091
Cristofanilli, 2002, Angiogenesis modulation in Cancer Research: novel clinical approaches, Nat. Rev., Drug Discov., 1, 415, 10.1038/nrd819
Schnaper, 1993, Type IV collagenase(s) and TIMPs modulate endothelial cell morphogenesis in vitro, J. Cell. Physiol., 156, 235, 10.1002/jcp.1041560204
Seftor, 2001, Cooperative interactions of laminin 5 gamma2 chain, matrix metalloproteinase-2, and membrane type-1-matrix/metalloproteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma, Cancer Res., 61, 6322
Puyraimond, 1999, Examining the relationship between the gelatinolytic balance and the invasive capacity of endothelial cells, J. Cell. Sci., 112, 1283, 10.1242/jcs.112.9.1283
Coussens, 2000, MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis, Cell, 103, 481, 10.1016/S0092-8674(00)00139-2
Joyce, 2004, Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis, Cancer Cell, 5, 443, 10.1016/S1535-6108(04)00111-4
Hangai, 2002, Matrix metalloproteinase-9-dependent exposure of a cryptic migratory control site in collagen is required before retinal angiogenesis, Am. J. Pathol., 161, 1429, 10.1016/S0002-9440(10)64418-5
Xu, 2001, Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo, J. Cell Biol., 154, 1069, 10.1083/jcb.200103111
Zhou, 2000, Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I, Proc. Natl. Acad. Sci. U. S. A., 97, 4052, 10.1073/pnas.060037197
Kang, 2003, A multigenic program mediating breast cancer metastasis to bone, Cancer Cell, 3, 537, 10.1016/S1535-6108(03)00132-6
van 't Veer, 2002, Gene expression profiling predicts clinical outcome of breast cancer, Nature, 415, 530, 10.1038/415530a
Itoh, 1999, Experimental metastasis is suppressed in MMP-9-deficient mice, Clin. Exp. Metastasis, 17, 177, 10.1023/A:1006603723759
Polette, 1994, Gelatinase A expression and localization in human breast cancers. An in situ hybridization study and immunohistochemical detection using confocal microscopy, Virchows Arch., 424, 641, 10.1007/BF01069745
Nelson, 2000, Matrix metalloproteinases: biologic activity and clinical implications, J. Clin. Oncol., 18, 1135, 10.1200/JCO.2000.18.5.1135
Hiratsuka, 2002, MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis, Cancer Cell, 2, 289, 10.1016/S1535-6108(02)00153-8
Klemke, 1994, Receptor tyrosine kinase signaling required for integrin alpha v beta 5-directed cell motility but not adhesion on vitronectin, J. Cell Biol., 127, 859, 10.1083/jcb.127.3.859
Filardo, 1995, Requirement of the NPXY motif in the integrin beta 3 subunit cytoplasmic tail for melanoma cell migration in vitro and in vivo, J. Cell Biol., 130, 441, 10.1083/jcb.130.2.441
Dunn, 2001, Up-regulation of urokinase-type plasminogen activator by insulin-like growth factor-I depends upon phosphatidylinositol-3 kinase and mitogen-activated protein kinase kinase, Cancer Res., 61, 1367
Yebra, 1996, Requirement of receptor-bound urokinase-type plasminogen activator for integrin alphavbeta5-directed cell migration, J. Biol. Chem., 271, 29393, 10.1074/jbc.271.46.29393
De, 2003, Molecular pathway for cancer metastasis to bone, J. Biol. Chem., 278, 39044, 10.1074/jbc.M304494200
Tremble, 1993, SPARC, a secreted protein associated with morphogenesis and tissue remodeling, induces expression of metalloproteinases in fibroblasts through a novel extracellular matrix-dependent pathway, J. Cell Biol., 121, 1433, 10.1083/jcb.121.6.1433
Sasaki, 1997, Limited cleavage of extracellular matrix protein BM-40 by matrix metalloproteinases increases its affinity for collagens, J. Biol. Chem., 272, 9237, 10.1074/jbc.272.14.9237
Sage, 2003, Cleavage of the matricellular protein SPARC by matrix metalloproteinase 3 produces polypeptides that influence angiogenesis, J. Biol. Chem., 278, 37849, 10.1074/jbc.M302946200
Koop, 1994, Overexpression of metalloproteinase inhibitor in B16F10 cells does not affect extravasation but reduces tumor growth, Cancer Res., 54, 4791
Morris, 1994, Mammary carcinoma cell lines of high and low metastatic potential differ not in extravasation but in subsequent migration and growth, Clin. Exp. Metastasis, 12, 357, 10.1007/BF01755879
Koop, 1996, Independence of metastatic ability and extravasation: metastatic ras-transformed and control fibroblasts extravasate equally well, Proc. Natl. Acad. Sci. U. S. A., 93, 11080, 10.1073/pnas.93.20.11080
Zijlstra, 2002, A quantitative analysis of rate-limiting steps in the metastatic cascade using human-specific real-time polymerase chain reaction, Cancer Res., 62, 7083
Udagawa, 2002, Persistence of microscopic human cancers in mice: alterations in the angiogenic balance accompanies loss of tumor dormancy, FASEB J., 16, 1361, 10.1096/fj.01-0813com
Soloway, 1996, Targeted mutagenesis of Timp-1 reveals that lung tumor invasion is influenced by Timp-1 genotype of the tumor but not by that of the host, Oncogene, 13, 2307
Barnhill, 1998, Tumor vascularity, proliferation, and apoptosis in human melanoma micrometastases and macrometastases, Arch. Dermatol., 134, 991, 10.1001/archderm.134.8.991
Kuper, 2000, Infections as a major preventable cause of human cancer, J. Intern. Med., 248, 171, 10.1046/j.1365-2796.2000.00742.x
Moore, 1998, CXC chemokines mechanism of action in regulating tumor angiogenesis, Angiogenesis, 2, 123, 10.1023/A:1009284305061
Nathanson, 2003, Insights into the mechanisms of lymph node metastasis, Cancer, 98, 413, 10.1002/cncr.11464
Muller, 2001, Involvement of chemokine receptors in breast cancer metastasis, Nature, 410, 50, 10.1038/35065016
Sheu, 2001, A novel role of metalloproteinase in cancer-mediated immunosuppression, Cancer Res., 61, 237
McQuibban, 2002, Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo, Blood, 100, 1160, 10.1182/blood.V100.4.1160.h81602001160_1160_1167
Williams, 1999, The role of cyclooxygenases in inflammation, cancer, and development, Oncogene, 18, 7908, 10.1038/sj.onc.1203286
Worthylake, 2001, Leukocyte transendothelial migration: orchestrating the underlying molecular machinery, Curr. Opin. Cell Biol., 13, 569, 10.1016/S0955-0674(00)00253-2
Brooks, 1994, Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels, Cell, 79, 1157, 10.1016/0092-8674(94)90007-8
Hammes, 1996, Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization, Nat. Med., 2, 529, 10.1038/nm0596-529
Reynolds, 2002, Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins, Nat. Med., 8, 27, 10.1038/nm0102-27
Hynes, 2002, A reevaluation of integrins as regulators of angiogenesis, Nat. Med., 8, 918, 10.1038/nm0902-918
Bader, 1998, Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all alpha v integrins, Cell, 95, 507, 10.1016/S0092-8674(00)81618-9
Pozzi, 2000, Elevated matrix metalloprotease and angiostatin levels in integrin alpha 1 knockout mice cause reduced tumor vascularization, Proc. Natl. Acad. Sci. U. S. A., 97, 2202, 10.1073/pnas.040378497
Pozzi, 2002, Low plasma levels of matrix metalloproteinase 9 permit increased tumor angiogenesis, Oncogene, 21, 272, 10.1038/sj.onc.1205045
Hamano, 2003, Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin, Cancer Cell, 3, 589, 10.1016/S1535-6108(03)00133-8
Balbin, 2003, Loss of collagenase-2 confers increased skin tumor susceptibility to male mice, Nat. Genet., 35, 252, 10.1038/ng1249
Coussens, 2002, Matrix metalloproteinase inhibitors and cancer: trials and tribulations, Science, 295, 2387, 10.1126/science.1067100
Pavlaki, 2003, Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials, Cancer Metastasis Rev., 22, 177, 10.1023/A:1023047431869
Bergers, 1999, Effects of angiogenesis inhibitors on multistage carcinogenesis in mice, Science, 284, 808, 10.1126/science.284.5415.808
Bremer, 2001, In vivo molecular target assessment of matrix metalloproteinase inhibition, Nat. Med., 7, 743, 10.1038/89126
Rosemurgy, 1999, Marimastat in patients with advanced pancreatic cancer: a dose-finding study, Am. J. Clin. Oncol., 22, 247, 10.1097/00000421-199906000-00007
Brown, 2000, Ongoing trials with matrix metalloproteinase inhibitors, Expert Opin. Investig. Drugs, 9, 2167, 10.1517/13543784.9.9.2167
Bramhall, 2002, Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial, Br. J. Cancer, 86, 1864, 10.1038/sj.bjc.6600310
Nyormoi, 2003, An MMP-2/MMP-9 inhibitor, 5a, enhances apoptosis induced by ligands of the TNF receptor superfamily in cancer cells, Cell Death Differ., 10, 558, 10.1038/sj.cdd.4401209
Haq, 2000, Addition of matrix metalloproteinase inhibition to conventional cytotoxic therapy reduces tumor implantation and prolongs survival in a murine model of human pancreatic cancer, Cancer Res., 60, 3207
Liu, 2003, Early combined treatment with carboplatin and the MMP inhibitor, prinomastat, prolongs survival and reduces systemic metastasis in an aggressive orthotopic lung cancer model, Lung Cancer, 42, 335, 10.1016/S0169-5002(03)00355-6
Yamamoto, 2003, A third-generation matrix metalloproteinase (MMP) inhibitor (ONO-4817) combined with docetaxel suppresses progression of lung micrometastasis of MMP-expressing tumor cells in nude mice, Int. J. Cancer, 103, 822, 10.1002/ijc.10875
Hoekstra, 2001, Matrix metalloproteinase inhibitors: current developments and future perspectives, Oncologist, 6, 415, 10.1634/theoncologist.6-5-415
Bramhall, 2002, A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer, Br. J. Cancer, 87, 161, 10.1038/sj.bjc.6600446
Kratz, 2001, Development and in vitro efficacy of novel MMP2 and MMP9 specific doxorubicin albumin conjugates, Bioorg. Med. Chem. Lett., 11, 2001, 10.1016/S0960-894X(01)00354-7
Mansour, 2003, A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2, Cancer Res., 63, 4062
Peng, 1997, A gene delivery system activatable by disease-associated matrix metalloproteinases, Hum. Gene Ther., 8, 729, 10.1089/hum.1997.8.6-729
Li, 2003, Imaging matrix metalloproteinase expression in tumors, Q. J. Nucl. Med., 47, 201
Goodson, 1994, High-affinity urokinase receptor antagonists identified with bacteriophage peptide display, Proc. Natl. Acad. Sci. U. S. A., 91, 7129, 10.1073/pnas.91.15.7129
Blasi, 2002, uPAR: a versatile signalling orchestrator, Nat. Rev., Mol. Cell Biol., 3, 932, 10.1038/nrm977
Shimaoka, 2003, Small molecule integrin antagonists that bind to the beta2 subunit I-like domain and activate signals in one direction and block them in the other, Immunity, 19, 391, 10.1016/S1074-7613(03)00238-3
Takagi, 2002, Global conformational rearrangements in integrin extracellular domains in outside-in and inside-out signaling, Cell, 110, 511, 10.1016/S0092-8674(02)00935-2
Xiong, 2001, Crystal structure of the extracellular segment of integrin alpha Vbeta3, Science, 294, 339, 10.1126/science.1064535
Kleifeld, 2001, X-ray absorption studies of human matrix metalloproteinase-2 (MMP-2) bound to a highly selective mechanism-based inhibitor. Comparison with the latent and active forms of the enzyme, J. Biol. Chem., 276, 17125, 10.1074/jbc.M011604200
Lazzarin, 2003, Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia, N. Engl. J. Med., 348, 2186, 10.1056/NEJMoa035211
Aimes, 1995, Matrix metalloproteinase-2 is an interstitial collagenase. Inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4- and 1/4-length fragments, J. Biol. Chem., 270, 5872, 10.1074/jbc.270.11.5872
Berton, 2000, Analysis of the ex vivo specificity of human gelatinases A and B towards skin collagen and elastic fibers by computerized morphometry, Matrix Biol., 19, 139, 10.1016/S0945-053X(00)00057-3
Seltzer, 1989, Cleavage of type VII collagen by interstitial collagenase and type IV collagenase (gelatinase) derived from human skin, J. Biol. Chem., 264, 3822, 10.1016/S0021-9258(19)84924-4
Cole, 1993, Type X collagen degradation in long-term serum-free culture of the embryonic chick tibia following production of active collagenase and gelatinase, Dev. Biol., 159, 528, 10.1006/dbio.1993.1261
Smith, 1991, Cleavage of type XI collagen fibers by gelatinase and by extracts of osteoarthritic canine cartilage, Matrix, 11, 36, 10.1016/S0934-8832(11)80225-8
Fosang, 1992, The interglobular domain of cartilage aggrecan is cleaved by PUMP, gelatinases, and cathepsin B, J. Biol. Chem., 267, 19470, 10.1016/S0021-9258(18)41799-1
Nakamura, 2000, Brevican is degraded by matrix metalloproteinases and aggrecanase-1 (ADAMTS4) at different sites, J. Biol. Chem., 275, 38885, 10.1074/jbc.M003875200
Imai, 1997, Degradation of decorin by matrix metalloproteinases: identification of the cleavage sites, kinetic analyses and transforming growth factor-beta1 release, Biochem. J., 322, 809, 10.1042/bj3220809
Murphy, 1991, Matrix metalloproteinase degradation of elastin, type IV collagen and proteoglycan. A quantitative comparison of the activities of 95 kDa and 72 kDa gelatinases, stromelysins-1 and -2 and punctuated metalloproteinase (PUMP), Biochem. J., 277, 277, 10.1042/bj2770277
Mayer, 1993, Sites of nidogen cleavage by proteases involved in tissue homeostasis and remodelling, Eur. J. Biochem., 217, 877, 10.1111/j.1432-1033.1993.tb18316.x
Sires, 1993, Degradation of entactin by matrix metalloproteinases. Susceptibility to matrilysin and identification of cleavage sites, J. Biol. Chem., 268, 2069, 10.1016/S0021-9258(18)53963-6
Ashworth, 1999, Fibrillin degradation by matrix metalloproteinases: implications for connective tissue remodelling, Biochem. J., 340, 171, 10.1042/0264-6021:3400171
Lelongt, 2001, Matrix metalloproteinase 9 protects mice from anti-glomerular basement membrane nephritis through its fibrinolytic activity, J. Exp. Med., 193, 793, 10.1084/jem.193.7.793
Bini, 1996, Degradation of cross-linked fibrin by matrix metalloproteinase 3 (stromelysin 1): hydrolysis of the gamma Gly 404-Ala 405 peptide bond, Biochemistry, 35, 13056, 10.1021/bi960730c
Nguyen, 1993, Matrix metalloproteinases cleave at two distinct sites on human cartilage link protein, Biochem. J., 295, 595, 10.1042/bj2950595
Larsen, 2003, Matrix metalloproteinase-9 facilitates remyelination in part by processing the inhibitory NG2 proteoglycan, J. Neurosci., 23, 11127, 10.1523/JNEUROSCI.23-35-11127.2003
Turk, 2001, Determination of protease cleavage site motifs using mixture-based oriented peptide libraries, Nat. Biotechnol., 19, 661, 10.1038/90273
Siri, 1995, Different susceptibility of small and large human tenascin-C isoforms to degradation by matrix metalloproteinases, J. Biol. Chem., 270, 8650, 10.1074/jbc.270.15.8650
Imai, 1995, Degradation of vitronectin by matrix metalloproteinases-1, -2, -3, -7 and -9, FEBS Lett., 369, 249, 10.1016/0014-5793(95)00752-U
Liu, 2000, The serpin alpha1-proteinase inhibitor is a critical substrate for gelatinase B/MMP-9 in vivo, Cell, 102, 647, 10.1016/S0092-8674(00)00087-8
Arbelaez, 1997, Interaction of matrix metalloproteinases-2 and -9 with pregnancy zone protein and alpha2-macroglobulin, Arch. Biochem. Biophys., 347, 62, 10.1006/abbi.1997.0309
Starckx, 2003, A novel rationale for inhibition of gelatinase B in multiple sclerosis: MMP-9 destroys alpha B-crystallin and generates a promiscuous T cell epitope, J. Neuroimmunol., 141, 47, 10.1016/S0165-5728(03)00217-0
LePage, 1995, Gelatinase A possesses a beta-secretase-like activity in cleaving the amyloid protein precursor of Alzheimer's disease, FEBS Lett., 377, 267, 10.1016/0014-5793(95)01358-X
Fernandez-Patron, 2002, Methods for analysis of matrix metalloproteinase regulation of neutrophil-endothelial cell adhesion, Biol. Proced. Online, 4, 38, 10.1251/bpo32
Ruiz, 1999, Digestion of C1q collagen-like domain with MMPs-1,-2,-3, and -9 further defines the sequence involved in the stimulation of neutrophil superoxide production, J. Leukoc. Biol., 66, 416, 10.1002/jlb.66.3.416
Van den Steen, 2000, Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact, Blood, 96, 2673, 10.1182/blood.V96.8.2673
Van Den Steen, 2003, Gelatinase B/MMP-9 and neutrophil collagenase/MMP-8 process the chemokines human GCP-2/CXCL6, ENA-78/CXCL5 and mouse GCP-2/LIX and modulate their physiological activities, Eur. J. Biochem., 270, 3739, 10.1046/j.1432-1033.2003.03760.x
Levi, 1996, Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1, Proc. Natl. Acad. Sci. U. S. A., 93, 7069, 10.1073/pnas.93.14.7069
Ochieng, 1994, Galectin-3 is a novel substrate for human matrix metalloproteinases-2 and -9, Biochemistry, 33, 14109, 10.1021/bi00251a020
Descamps, 2003, Gelatinase B is diabetogenic in acute and chronic pancreatitis by cleaving insulin, FASEB J., 17, 887, 10.1096/fj.02-0725fje
Fowlkes, 1994, Matrix metalloproteinases degrade insulin-like growth factor-binding protein-3 in dermal fibroblast cultures, J. Biol. Chem., 269, 25742, 10.1016/S0021-9258(18)47310-3
Manes, 1999, The matrix metalloproteinase-9 regulates the insulin-like growth factor-triggered autocrine response in DU-145 carcinoma cells, J. Biol. Chem., 274, 6935, 10.1074/jbc.274.11.6935
Thrailkill, 1995, Characterization of insulin-like growth factor-binding protein 5-degrading proteases produced throughout murine osteoblast differentiation, Endocrinology, 136, 3527, 10.1210/en.136.8.3527
Nelissen, 2003, Gelatinase B/matrix metalloproteinase-9 cleaves interferon-beta and is a target for immunotherapy, Brain, 126, 1371, 10.1093/brain/awg129
Van den Steen, 2003, Carboxyterminal cleavage of the chemokines MIG and IP-10 by gelatinase B and neutrophil collagenase, Biochem. Biophys. Res. Commun., 310, 889, 10.1016/j.bbrc.2003.09.098
Takino, 2003, Cleavage of metastasis suppressor gene product KiSS-1 protein/metastin by matrix metalloproteinases, Oncogene, 22, 4617, 10.1038/sj.onc.1206542
Heissig, 2002, Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand, Cell, 109, 625, 10.1016/S0092-8674(02)00754-7
Chandler, 1995, Matrix metalloproteinases degrade myelin basic protein, Neurosci. Lett., 201, 223, 10.1016/0304-3940(95)12173-0
Rouet-Benzineb, 1999, Altered balance between matrix gelatinases (MMP-2 and MMP-9) and their tissue inhibitors in human dilated cardiomyopathy: potential role of MMP-9 in myosin-heavy chain degradation, Eur. J. Heart Fail., 1, 337, 10.1016/S1388-9842(99)00048-3
O'Reilly, 1999, Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance, J. Biol. Chem., 274, 29568, 10.1074/jbc.274.41.29568
Patterson, 1997, Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9), J. Biol. Chem., 272, 28823, 10.1074/jbc.272.46.28823
Schonbeck, 1998, Generation of biologically active IL-1 beta by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1 beta processing, J. Immunol., 161, 3340, 10.4049/jimmunol.161.7.3340
Crabbe, 1994, Reciprocated matrix metalloproteinase activation: a process performed by interstitial collagenase and progelatinase A, Biochemistry, 33, 14419, 10.1021/bi00252a007
Crabbe, 1993, Human progelatinase A can be activated by autolysis at a rate that is concentration-dependent and enhanced by heparin bound to the C-terminal domain, Eur. J. Biochem., 218, 431, 10.1111/j.1432-1033.1993.tb18393.x
Ray, 2003, Members of the cystatin superfamily interact with MMP-9 and protect it from autolytic degradation without affecting its gelatinolytic activities, Biochim. Biophys. Acta, 1652, 91, 10.1016/j.bbapap.2003.08.004
Knauper, 1996, Cellular mechanisms for human procollagenase-3 (MMP-13) activation. Evidence that MT1-MMP (MMP-14) and gelatinase a (MMP-2) are able to generate active enzyme, J. Biol. Chem., 271, 17124, 10.1074/jbc.271.29.17124
Gearing, 1994, Processing of tumour necrosis factor-alpha precursor by metalloproteinases, Nature, 370, 555, 10.1038/370555a0
McQuibban, 2001, Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1, J. Biol. Chem., 276, 43503, 10.1074/jbc.M107736200
Backstrom, 1995, The 84-kDa form of human matrix metalloproteinase-9 degrades substance P and gelatin, J. Neurochem., 64, 1312, 10.1046/j.1471-4159.1995.64031312.x
Wang, 2002, Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury, Circulation, 106, 1543, 10.1161/01.CIR.0000028818.33488.7B
Hill, 1995, Inhibition of bone resorption in vitro by selective inhibitors of gelatinase and collagenase, Biochem. J., 308, 167, 10.1042/bj3080167